A preclinical study demonstrated that the combination of ATR inhibitor AZD6738 with radiotherapy resulted in enhanced tumor-infiltrating CD8+ T cell activity in CT26 mouse colon cancer cells by blocking radiation-induced PD-L1 expression and significantly reducing the number of tumor-infiltrating Treg. The gene discussed is ATR; the disease is neoplasm.